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Antiphospholipid Syndrome 
Background  
1. Definitions  
o Hypercoagulable disorder characterized by  
 Increased vascular thrombosis 
 Recurrent miscarriages 
 Thrombocytopenia 
2. General info  
o Pregnancy complications with APS  
 Pregnancy-related maternal thrombosis  
 Late fetal death 
 Early severe preeclampsia 
 Fetal growth restriction 
 Recurrent pregnancy loss 
o Two types of APS  
 Primary (occurring as isolated syndrome)  
 Secondary (relating to other disease or risk factor such as systemic lupus 
erythematosus (SLE)  
 
Pathophysiology  
1. Pathology of disease  
o Increased thrombogenesis possibly via
1
 
 High levels of lupus anticoagulant (LA) and anticardiolipin antibody 
(aCL) 
 Reduced level of anticoagulant annexin V 
 Antibody against Factor XII
2
 
 Increase in tissue factor 
o Higher complement activation likely associated with adverse events of pregnancy 
in women with APS
3
 
2. Incidence, prevalence4 
o Antibodies found in  
 5-10% of healthy individuals  
 30-50% of individuals with SLE  
 4-21% of individuals with thrombosis 
o Anticardiolipin antibodies  
 Found in up to 11% of uncomplicated pregnancies  
 Associated with up to 10% of recurrent pregnancy losses 
3. Risk factors4 
o SLE  
o HIV  
o Cancer  
o Drugs  
 Procainamide 
 Hydralazine  
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 Chlorpromazine 
 Oral contraceptives  
4. Morbidity / mortality5 
o Pregnant patients with APS: risk of thrombosis is 5-12%
6
 
 If history of recurrent fetal loss but no thrombosis, risk of thrombosis in 
subsequent pregnancy increases to 10% or higher 
o Decreased live birth rate in women with APS (62-84% vs 90-98% in women 
without antibodies)
4
 
o Significant association with
6
 
 Preeclampsia  
 Severe preeclampsia 
 HELLP syndrome  
 Hemolytic anemia 
 Thrombocytopenia 
o High association with SLE and chronic inflammation  
 APS patients at higher risk for MI, CVA, nephropathy (in secondary APS 
due to SLE), and cognitive delays
5
 
 
Diagnostics  
1. History  
o Can be asymptomatic 
o Recurrent pregnancy loss  
o History of thromboembolism  
o Presentation: symptoms of  
 Spontaneous miscarriage (SAB)  
 Thrombosis or embolism 
2. Physical examination5 
o Signs of thromboembolism  
 DVT is present in 32% 
 PE in 9%  
o Livedo reticularis  
 Seen in 20% of APS patients 
 Reticular pattern of erythema and/or cyanosis  
 Suggestive of arterial disease 
o Vascular disease  
 CVA seen in 9% 
 Phlebitis, ulceration, necrosis of skin or digits 
o Less common
5
 
 Murmur, splinter hemorrhages suggestive of valvular disease or 
endocarditis  
 Amaurosis fugax  
 Chorea  
 Splenomegaly 
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3. Diagnostic testing4,5,6,7 
o Laboratory evaluation  
 Presence of LA 
 High titer of aCL IgG or IgM (>20 units) 
o Diagnostic imaging  
 Ultrasound or CT to verify thrombosis 
o Other studies  
 Directed toward co-morbidities 
 Platelet count 
 Urinalysis and urine protein if concern for preeclampsia or nephropathy 
 Echocardiogram if suspect endocarditis  
 CMP if concern for hepatic or renal complications 
4. Diagnostic "Criteria"4,5,7  
o Sapporo Criteria (SOR:B)
4,5
  
 At least one clinical criteria 
 Recurrent fetal loss prior to 10th week 
 Arterial, venous, or small vessel thrombosis 
 Unexplained fetal demise after 10th week 
 Preterm parturition due to placental insufficiency, preeclampsia, or 
eclampsia 
 And one laboratory criteria 
 aCL or LA  
 Present on 2 or more occasions 6 or more weeks apart 
 No evidence to suggest that use of Sapporo Criteria are superior to one-
time test of APS antibodies in symptomatic patients (SOR:B)
4,5,8
 
 
Differential Diagnosis  
1. Key differential diagnoses  
o Autoimmune disease  
 SLE  
o Thrombophilia of pregnancy  
 Factor V Leiden (Activated Protein C Resistance) 
 Prothrombin G20210A mutation 
 Protein C deficiency 
 Protein S deficiency 
 Antithrombin III deficiency 
 Dysfibrinogenemias 
 Elevated factor VIII or prothrombin 
o Vasculitis  
o Hyperhomocysteinemia 
o Malignancy  
2. Extensive differential diagnoses  
o Hypertension  
o Diabetes mellitus  
o Hypothyroidism  
o Trauma  
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o Nephrotic syndrome  
o HIV  
o Sepsis  
o Liver disease 
o Septate uterus or other anatomic lesion of uterus 
o Incompetent cervix  
o Luteal phase insufficiency (progesterone insufficiency) 
o Intrauterine adhesions 
o Polycystic ovary syndrome  
o Fetal chromosomal defect 
o Carcinoma/malignancy 
o Behcet's disease 
o Buerger's disease 
o TTP 
o DIC  
o Sickle cell anemia  
o Polycythemia vera 
o Inflammatory bowel disease  
o Heparin-induced thrombocytopenia  
 
Therapeutics  
1. Acute treatment  
o ABCs if severe clotting, blood loss, or hemodynamic instability 
o Management of thromboembolism (if present)  
o Management of fetal loss (if present)  
o Multidisciplinary approach and appropriate medical management 
o If known APS or criteria for APS, aspirin 81mg/day for patients
4,6,8
  
 Attempting conception AND  
 Have 2 or more early pregnancy losses or one or more late pregnancy 
losses 
2. Further management (24 hrs)  
o With conception, once daily heparin (5,000-10,000 units), LMWH (1 mg/kg), or 
dalteparin (5,000 units)
6,8
  
o Interdisciplinary team approach with obstetrician or maternal-fetal medicine  
3. Long-term care  
o Serial ultrasounds looking for IUGR and other complications
6
  
o Combined unfractionated heparin (5,000 units BID) and aspirin (75-81 mg/day) 
may reduce pregnancy loss compared to aspirin alone  
o No difference noted between high- or low-dose unfractionated heparin
9
  
o No pregnancy loss reduction was seen with low molecular weight heparin and 
aspirin compared to aspirin alone
9
  
o Aspirin alone (75-81 mg/day) did not reduce pregnancy loss compared to 
placebo
9
 
o Glucocorticoids do not prevent pregnancy loss and may be associated with 
increased complications and pre-term birth
9
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o IVIG with or without unfractionated heparin or aspirin associated with increased 
risk of pregnancy loss
9
  
o Continued thromboprophylaxis 6 weeks post-partum
4,6,8
  
4. Summary treatment recommendations  
o Optimal management uncertain (SOR:A)
4,8,9
  
o Women with APS may benefit from aspirin during attempted conception 
(SOR:B)
8
  
o Pregnant patients with known APS with history of fetal loss:  
 Best treated with combination aspirin 81mg and unfractionated heparin 
(SOR:B)
9
  
 Glucocorticoids, and Intravenous Immunoglobulin are not helpful and 
appear to be associated with worse outcomes (SOR:B)
9
  
 Continued thromboprophylaxis 6 weeks post-partum (SOR:B)
4,8
  
 
Prognosis  
1. Unclear if any increased risk with low levels of antibodies4 
2. High levels of antibodies and a history of thrombosis are associated with increased risk of 
recurrent adverse events of pregnancy even with anticoagulation
4,6
  
3. Women with 3 or more SABs, a normal ultrasound after 6-8 weeks yields a 80% chance 
of live birth
5
 
 
Prevention 
1. No indications or recommendations exist for routine screening of asymptomatic women 
without history of recurrent losses or thrombotic events (SOR:B)
6
  
2. Aspirin 81mg per day may be helpful in non-pregnant women with APS4 
3. Education and counseling 
4. Avoidance of tobacco 
5. Control of co-morbid diagnoses 
 
Patient Education 
1. NIH: http://www.nhlbi.nih.gov/health/dci/Diseases/aps/aps_what.html 
2. American Reproductive Society: 
http://www.asrm.org/Patients/FactSheets/recurrent_preg_loss.pdf 
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